Today, the VP & GC of Cryolife, Jean Holloway, exercised options of Cryolife (NYSE: CRY) for $13.97K. The options were close to expired and Jean Holloway retained stocks.
This is Holloway’s first transaction since reporting a Sell transaction on BCR back in July 2013 In addition to Jean Holloway, 3 other CRY executives reported Buy trades in the last month.
See today’s analyst top recommended stocks >>
Based on Cryolife’s latest earnings report for the quarter ending March 31, the company posted quarterly revenue of $61.95 million and GAAP net loss of $3.82 million. In comparison, last year the company earned revenue of $47.82 million and had a net profit of $3.1 million. Currently, Cryolife has an average volume of 95.29K.
Starting in April 2016, CRY received 46 Buy ratings in a row. Four different firms, including Canaccord Genuity and Northland Securities, currently also have a Buy rating on the stock.
In the last 30 days, insiders have sold $144.4K worth of CRY shares and purchased $36.21K worth of CRY shares. The insider sentiment on Cryolife has been negative according to 77 insider trades in the past three months. This sentiment is lower than the average sentiment of company insiders in this sector.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CryoLife, Inc. is a medical devices company, which engages in the processing and distribution of implantable human tissues for use in cardiac and vascular surgeries. It operates through the Medical Devices and Preservation Services segments.
